Logo image of GRTS

GRITSTONE BIO INC (GRTS) Stock Price, Quote, News and Overview

NASDAQ:GRTS - Nasdaq - US39868T1051 - Common Stock - Currency: USD

0.0322  -0.01 (-31.78%)

After market: 0.026 -0.01 (-19.25%)

GRTS Quote, Performance and Key Statistics

GRITSTONE BIO INC

NASDAQ:GRTS (10/21/2024, 8:17:44 PM)

After market: 0.026 -0.01 (-19.25%)

0.0322

-0.01 (-31.78%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High3.17
52 Week Low0.03
Market Cap3.80M
Shares118.11M
Float115.25M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)11-07 2024-11-07/amc
IPO09-28 2018-09-28


GRTS short term performance overview.The bars show the price performance of GRTS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60 -80

GRTS long term performance overview.The bars show the price performance of GRTS in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of GRTS is 0.0322 USD. In the past month the price decreased by -94.46%. In the past year, price decreased by -98.3%.

GRITSTONE BIO INC / GRTS Daily stock chart

GRTS Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.97 357.10B
AMGN AMGEN INC 15.29 162.72B
GILD GILEAD SCIENCES INC 23.85 137.00B
VRTX VERTEX PHARMACEUTICALS INC 1669.79 124.40B
REGN REGENERON PHARMACEUTICALS 15.34 76.56B
ARGX ARGENX SE - ADR N/A 39.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.32B
BNTX BIONTECH SE-ADR N/A 28.77B
ONC BEIGENE LTD-ADR N/A 27.25B
NTRA NATERA INC N/A 21.43B
BIIB BIOGEN INC 8.54 20.49B
SMMT SUMMIT THERAPEUTICS INC N/A 16.31B

About GRTS

Company Profile

GRTS logo image Gritstone bio, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company is headquartered in Emeryville, California and currently employs 231 full-time employees. The company went IPO on 2018-09-28. The firm discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates. The company has developed two vectors that it deploys with the aim of eliciting the desired immune response: self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. The company has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate. In oncology, it develops personalized vaccines that aim to destroy tumors through CD8+ (killer) T cell recognition of tumor cells by virtue of their surface display of neoantigens.

Company Info

GRITSTONE BIO INC

5959 Horton Street, Suite 300

Emeryville CALIFORNIA 94608 US

CEO: Andrew Allen

Employees: 231

Company Website: https://gritstonebio.com/

Phone: 15108716100

GRITSTONE BIO INC / GRTS FAQ

What is the stock price of GRITSTONE BIO INC today?

The current stock price of GRTS is 0.0322 USD. The price decreased by -31.78% in the last trading session.


What is the ticker symbol for GRITSTONE BIO INC stock?

The exchange symbol of GRITSTONE BIO INC is GRTS and it is listed on the Nasdaq exchange.


On which exchange is GRTS stock listed?

GRTS stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for GRITSTONE BIO INC stock?

6 analysts have analysed GRTS and the average price target is 0.77 USD. This implies a price increase of 2275.78% is expected in the next year compared to the current price of 0.0322. Check the GRITSTONE BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is GRITSTONE BIO INC worth?

GRITSTONE BIO INC (GRTS) has a market capitalization of 3.80M USD. This makes GRTS a Nano Cap stock.


How many employees does GRITSTONE BIO INC have?

GRITSTONE BIO INC (GRTS) currently has 231 employees.


Is GRITSTONE BIO INC (GRTS) expected to grow?

The Revenue of GRITSTONE BIO INC (GRTS) is expected to decline by -74.34% in the next year. Check the estimates tab for more information on the GRTS EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy GRITSTONE BIO INC (GRTS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does GRITSTONE BIO INC (GRTS) stock pay dividends?

GRTS does not pay a dividend.


When does GRITSTONE BIO INC (GRTS) report earnings?

GRITSTONE BIO INC (GRTS) will report earnings on 2024-11-07, after the market close.


What is the Price/Earnings (PE) ratio of GRITSTONE BIO INC (GRTS)?

GRITSTONE BIO INC (GRTS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.09).


GRTS Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

GRTS Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to GRTS. GRTS may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

GRTS Financial Highlights

Over the last trailing twelve months GRTS reported a non-GAAP Earnings per Share(EPS) of -1.09. The EPS increased by 13.49% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -93.33%
ROE -599.53%
Debt/Equity 1.83
Chartmill High Growth Momentum
EPS Q2Q%48.39%
Sales Q2Q%-52.89%
EPS 1Y (TTM)13.49%
Revenue 1Y (TTM)25.14%

GRTS Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 43% to GRTS. The Buy consensus is the average rating of analysts ratings from 6 analysts.

For the next year, analysts expect an EPS growth of 19.29% and a revenue growth -74.34% for GRTS


Ownership
Inst Owners30.17%
Ins Owners7.44%
Short Float %N/A
Short RatioN/A
Analysts
Analysts43.33
Price Target0.77 (2291.3%)
EPS Next Y19.29%
Revenue Next Year-74.34%